

Title	Two-staged treatment strategy in patients with severe carotid or cerebrovascular diseases undergoing coronary artery bypass grafting.
Author(s)	Okamoto, Yuki; Minakata, Kenji; Yunoki, Tomoyuki; Katsu, Masatake; Chino, Shin-Ichiro; Matsumoto, Masahiko
Citation	General thoracic and cardiovascular surgery (2011), 59(11): 730-736
Issue Date	2011-11
URL	<a href="http://hdl.handle.net/2433/151851">http://hdl.handle.net/2433/151851</a>
Right	The final publication is available at <a href="http://www.springerlink.com">www.springerlink.com</a>
Type	Journal Article
Textversion	author

Editorial Manager(tm) for General Thoracic and Cardiovascular Surgery  
Manuscript Draft

Manuscript Number:

Title: Treatment of Prosthetic Valve Endocarditis Complicated with Destruction of the Aortic Annulus

Article Type: Original Article

Keywords: prosthetic valve endocarditis; aortic annular abscess; patch plasty

Corresponding Author: Kenji Minakata, M.D., Ph.D

Corresponding Author's Institution: Kyoto University Graduate School of Medicine

First Author: Yuki Okamoto, M.D.

Order of Authors: Yuki Okamoto, M.D.;Kenji Minakata, M.D., Ph.D;Tomoyuki Yunoki, M.D.;Masatake Katsu, M.D., Ph.D.;Shin-ichiro Chino, M.D.;Masahiko Matsumoto, M.D., Ph.D.

**Abstract:** Objective: It has been reported that surgical treatment for prosthetic valve endocarditis complicated with destruction of the aortic annulus is associated with high mortality and morbidity. We use a relatively simple procedure consisting of a patch plasty of the abscess cavity, in addition to complete removal of the infected tissue of the abscess cavity followed by a standard aortic valve replacement.

**Methods:** Between October 2003 and April 2009, 8 patients (7 males; mean age,  $68.6 \pm 9.8$  years) with prosthetic valve endocarditis complicated with destruction of the aortic annulus were surgically treated at Tominaga hospital. All patients were in New York Heart Association functional class III or IV. All patients had active endocarditis. Preoperative echocardiography revealed that 4 patients had moderate or severe aortic regurgitation, and 2 patients had mitral valve endocarditis as well.

**Results:** There were no operative deaths ( $\leq 30$  days). Cardiac complications included paroxysmal atrial fibrillation in 3 patients and transient atrioventricular block in one. One patient died of multiple organ failure 66 days after the surgery. The overall in-hospital mortality was 12.5%. Patients were followed-up for 6 to 49 months (mean,  $31 \pm 19$  months). There was no recurrent prosthetic valve endocarditis. One patient required reoperation (mitral annuloplasty and redo aortic valve replacement) mainly due to severe functional mitral regurgitation. There were 2 late deaths: lung cancer in 1 and multiple organ failure related to pneumonia after the aforementioned redo operation.

**Conclusion:** Our simple procedure for complicated prosthetic valve endocarditis yielded excellent early and mid-term outcomes.

1  
2  
3 Treatment of Prosthetic Valve Endocarditis Complicated with Destruction of the Aortic  
4  
5 Annulus  
6  
7  
8  
9

10 Yuki Okamoto, MD<sup>1</sup>

11  
12 Kenji Minakata, MD, PhD<sup>1</sup>

13  
14 Tomoyuki Yunoki, MD<sup>1</sup>

15  
16 Masatake Katsu, MD, PhD<sup>1</sup>

17  
18  
19 Shin-ichiro Chino, MD<sup>1</sup>

20  
21  
22 Masahiko Matsumoto, MD, PhD<sup>2</sup>  
23  
24  
25

26  
27 <sup>1</sup>Division of Cardiovascular Surgery, Tominaga Hospital, Osaka, Japan  
28

29 <sup>2</sup>Second Department of Surgery, University of Yamanashi, Yamanashi, Japan  
30  
31  
32  
33

34 **Corresponding author:** Kenji Minakata  
35

36 **Mailing address:** Department of Cardiovascular Surgery, Kyoto University Graduate  
37  
38 School of Medicine, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto, Japan 606-8507  
39  
40

41 **Tel:** +81-75-751-3780  
42

43 **FAX:** +81-75-751-3098  
44

45 **Email:** [minakata@kuhp.kyoto-u.ac.jp](mailto:minakata@kuhp.kyoto-u.ac.jp)  
46  
47  
48  
49

50 **Key words:** prosthetic valve endocarditis, aortic annular abscess, patch plasty  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Abstract**

**Objective:** It has been reported that surgical treatment for prosthetic valve endocarditis complicated with destruction of the aortic annulus is associated with high mortality and morbidity. We use a relatively simple procedure consisting of a patch plasty of the abscess cavity, in addition to complete removal of the infected tissue of the abscess cavity followed by a standard aortic valve replacement.

**Methods:** Between October 2003 and April 2009, 8 patients (7 males; mean age,  $68.6 \pm 9.8$  years) with prosthetic valve endocarditis complicated with destruction of the aortic annulus were surgically treated at our hospital. All patients were in New York Heart Association functional class III or IV. All patients had active endocarditis. Preoperative echocardiography revealed that 4 patients had moderate or severe aortic regurgitation, and 2 patients had mitral valve endocarditis as well.

**Results:** There were no operative deaths ( $\leq 30$  days). Cardiac complications included paroxysmal atrial fibrillation in 3 patients and transient atrioventricular block in one. One patient died of multiple organ failure 66 days after the surgery. The overall in-hospital mortality was 12.5%. Patients were followed-up for 6 to 49 months (mean,  $31 \pm 19$  months). There was no recurrent prosthetic valve endocarditis. One patient required reoperation (mitral annuloplasty and redo aortic valve replacement) mainly due to severe functional mitral regurgitation. There were 2 late deaths: lung cancer in 1 and multiple organ failure related to pneumonia after the aforementioned redo operation.

**Conclusion:** Our simple procedure for complicated prosthetic valve endocarditis yielded excellent early and mid-term outcomes.

## Introduction

Prosthetic valve endocarditis (PVE) is a serious complication that can follow aortic valve replacement, and severe PVE often destroys the aortic annulus, leading to “aorto-left ventricular discontinuity.” Periannular abscesses occur in a significant number of PVE patients, occurring in 56% to 100% of affected patients.<sup>1,2</sup> Moreover, when destruction of the aortic annulus is present in patients with PVE, hemodynamic instability can easily occur as a result of the uncontrollable septic state associated with abscess formation, perivalvular leakage, prosthetic valve malfunction or conduction disturbances. These patients require complex surgical interventions in addition to aggressive antibiotic therapy.<sup>1,2</sup> Therefore, multiple surgical techniques have been proposed for complex reconstruction to improve mortality and morbidity in PVE patients with destruction of the aortic annulus.

Previous studies have reported good outcomes with aortic root replacement using homografts, which are thought to be more resistant to bacterial or fungal infections than prosthetic valves.<sup>3-9</sup> In Japan, the supply of homografts is very limited, and as an alternative approach, the Ross procedure has been performed in some institutions with excellent results.<sup>9</sup> However, the Ross procedure is technically demanding and requires longer cross-clamp time and cardiopulmonary bypass time, potentially increasing mortality and morbidity.

Since 2003, we have performed a relatively simple procedure for PVE complicated with destruction of the aortic annulus. Our technique includes patch reconstruction of the aortic annulus followed by placement of a new prosthetic valve in addition to aggressive removal of the infected tissue and drainage of the abscess cavity.

The aim of this study was to evaluate the efficacy of our surgical strategy for PVE

1  
2  
3 complicated with destruction of the aortic annulus.  
4  
5  
6

## 7 **Patients and Methods**

### 8 Patients

9  
10  
11  
12 Between October 2003 and April 2009, 8 patients were admitted to Tominaga hospital  
13 with a diagnosis of PVE complicated with destruction of the aortic annulus. These  
14 patients formed the cohort for this study. In all of these patients, diagnosis was made  
15 based on the Duke criteria.<sup>1,10</sup>  
16  
17  
18  
19  
20  
21

22 The patient demographics and clinical characteristics are summarized in Table 1. The  
23 mean age was  $68.6 \pm 9.8$  years (range, 53 to 84 years) and 7 patients were male. All  
24 patients were in New York Heart Association (NYHA) functional class III or IV and had  
25 active infection. The median interval between the initial and the redo operation was  $5.5$   
26  $\pm 6.1$  months (range of 1.9 to 20.3 months). In terms of the onset of infection<sup>11</sup>, there  
27 was 1 case of early PVE (onset within two months of the initial operation) and 7 cases  
28 of late PVE (onset more than 2 months after the initial operation). Two patients had had  
29 dental treatment within 1 month prior to the onset of the PVE episode.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 For the initial aortic valve replacement (AVR), isolated AVR was performed in 4  
42 patients and AVR with additional surgical procedures was performed in 4 (Table 1). A  
43 permanent pacemaker was implanted in patient 7 due to sick sinus syndrome and patient  
44 8 had a minor stroke after the operation, while the other patients had no postoperative  
45 complications.  
46  
47  
48  
49  
50  
51  
52

53 In terms of infectious agents, the microorganisms causing PVE were  
54 methicillin-resistant *Staphylococcus epidermidis* (MRSE) in 5 patients,  
55 methicillin-sensitive *Staphylococcus epidermidis* (MSSE) in 1, and unknown in 2.  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 The preoperative echocardiographic data are shown in Table 1. Left ventricular  
4 function was relatively preserved in this cohort, with a mean left ventricular ejection  
5 fraction (LVEF) of  $57 \pm 18\%$ , although 2 patients had significantly depressed LVEF  
6 (25% and 35%). Visible vegetation on the aortic prosthesis was usually identified by  
7 either transthoracic or transesophageal echocardiography. Perivalvular leakage was  
8 common, with moderate or severe aortic regurgitation (AR) in 4 patients. Pressure  
9 gradients across the prosthetic valve were commonly elevated because of restricted  
10 mobility of leaflets and obstruction of left ventricular outflow due to the presence of  
11 abscesses formation. Two patients were found to have vegetation on the mitral valve as  
12 well.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

27 Indications for surgery were advancing congestive heart failure in 1 patient and  
28 uncontrollable infection despite aggressive antibiotic treatment in 7.  
29  
30  
31  
32  
33

### 34 Surgical Technique

35

36 Surgery was performed via median sternotomy with the use of extracorporeal  
37 circulation and mild systemic hypothermia. Myocardial protection was accomplished by  
38 antegrade and, if feasible, retrograde cold blood cardioplegia. The left ventricle was  
39 vented by cannulation through the right superior pulmonary vein.  
40  
41  
42  
43  
44  
45

46 Our surgical strategy for PVE complicated with destruction of the aortic annulus  
47 consisted of radical debridement (complete removal of infected or necrotic tissue with a  
48 curette) and irrigation of the abscess cavity with large amount of saline solution. Most  
49 times, patch reconstruction of the left ventricular outflow tract at the level of and below  
50 the aortic annulus was required using equine pericardium with a 5-0 polypropylene  
51 running suture, and fibrin glue mixed with antibiotics (vancomycin or gentamicin) was  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 injected into the cavity. When the aortic annulus was reconstructed, AVR was performed  
4  
5 with pledgeted mattress sutures passed through both the patch and the aortic wall to  
6  
7 securely anchor the prosthetic valve to the reconstructed aortic annulus. Sometimes, the  
8  
9 sutures were passed from outside the aortic wall to pass through enough tissue to  
10  
11 stabilize the prosthesis. Postoperatively, sufficient antibiotics were administered  
12  
13 intravenously for at least 4 to 6 weeks, and then oral antibiotics were given for at least  
14  
15 several months.  
16  
17  
18  
19  
20

## 21 **Results**

### 22 Operative and Early Postoperative Results

23  
24  
25 The operative results are shown in Table 2. There were no intraoperative nor operative  
26  
27 deaths (<30 days). As shown in Figure 1, abscess cavities were found in the entire aortic  
28  
29 annulus in 4 patients (this was classified as “aorto-left ventricular discontinuity”). None  
30  
31 of these patients had any abscess formation beyond the sinus of Valsalva or near the  
32  
33 coronary ostia. In 2 patients, direct closure of the cavity was feasible because the  
34  
35 abscess cavity was small (only a 3-5mm gap was identified). AVR was performed using  
36  
37 biological valves in 4 patients and mechanical valves in 4. Patient 6 had vegetation on  
38  
39 both aortic and mitral prostheses, which necessitated redo mitral valve replacement  
40  
41 using the standard technique. In patient 7, we removed vegetation attached to the native  
42  
43 mitral valve in addition to AVR.  
44  
45  
46  
47  
48

49  
50 All patients were successfully weaned from cardiopulmonary bypass, but 3 patients  
51  
52 required an intra-aortic balloon pump to achieve hemodynamic stability. The mean  
53  
54 cardiopulmonary bypass time was  $213 \pm 82$  minutes (range, 112 to 367 minutes), and  
55  
56 the mean aortic cross clamp time was  $145 \pm 45$  minutes (range, 86 to 232 minutes). All  
57  
58  
59  
60  
61  
62  
63  
64  
65



1  
2  
3 the patients left the operation room without significant aortic regurgitation (AR; defined  
4  
5 as mild or less).  
6

7 As shown in Table 2, patient 8 developed multiple complications, including general  
8  
9 prostration caused by infectious colitis, renal dysfunction and pneumonia, and  
10  
11 eventually died of multiple organ failure 66 days after the operation. The overall  
12  
13 in-hospital mortality rate was 12.5%. The median postoperative respiratory support time  
14  
15 was 27 hours (range, 12 to 184 hours) and the mean hospital stay, excluding the one of  
16  
17 hospital death, was  $65 \pm 22$  days (range, 34 to 92 days). During the hospital stays, 3  
18  
19 patients developed paroxysmal atrial fibrillation and 1 patient developed transient  
20  
21 atrioventricular block which did not required permanent pacemaker implantation.  
22  
23 Patient 6 required sternal wound re-exploration for postoperative bleeding. Patient 7 had  
24  
25 refractory gastrointestinal bleeding and also required prolonged respiratory support. No  
26  
27 patients had recurrent infection on prosthetic valves or sepsis. Echocardiographic  
28  
29 examination on discharge revealed that two patients had developed moderate AR.  
30  
31  
32  
33  
34  
35  
36  
37  
38

### 39 Mid-Term Follow-up Results

40  
41 Patients were followed up for 6 to 49 months, with a mean of  $31 \pm 19$  months. Patient 1  
42  
43 was lost to follow-up at 8 months after surgery. Patient 2 required re-operation (mitral  
44  
45 annuloplasty and redo AVR) mainly due to severe functional MR 32 months after the  
46  
47 previous redo AVR. This was essentially associated with poor left ventricular function  
48  
49 and a dilated left ventricle. Repeat AVR was also performed because this patient had  
50  
51 moderate AR due to perivalvular leakage. Of note, there was no evidence of recurrent  
52  
53 infection around the aortic root. This patient died of multiple organ failure related to  
54  
55 refractory pneumonia 3 months later. Patient 6 died of lung cancer 6 months after the  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 operation.

4  
5 Follow-up echocardiography demonstrated that 2 patients had moderate AR without  
6  
7 hemodynamic instability. Four patients continue to be followed up at our institution and  
8  
9 are in NYHA functional class I or II with no signs of recurrent PVE.  
10

## 11 12 13 14 15 **Discussion**

16  
17 PVE complicated with destruction of the aortic annulus is a potentially fatal  
18  
19 complication of AVR. The surgical treatment of this condition is challenging, with  
20  
21 operative mortality rates ranging from 7.3% to 33%.<sup>1,2,12-14</sup> This high mortality is  
22  
23 associated with preoperative hemodynamic deterioration due to uncontrolled sepsis  
24  
25 from abscess formation, valve malfunction, multiple organ involvement due to severe  
26  
27 infection and low cardiac output, and the complexity of the surgical procedure.<sup>1,2</sup>  
28  
29 Because the surgical mortality rate of the third redo operation for recurrent PVE can be  
30  
31 as high as 55.6%,<sup>15</sup> it is very important to choose a surgical strategy that decreases the  
32  
33 recurrence of PVE.  
34  
35  
36

37  
38 The surgical management of PVE complicated with an aortic annular abscess  
39  
40 involves aggressive and complete debridement of all infected or necrotic tissue,  
41  
42 reconstruction of the damaged annulus and restoration of valve function. Many authors  
43  
44 have reported that extended debridement and resection of infected paravalvular tissue  
45  
46 are more important than the materials used for the reconstruction of the aortic  
47  
48 valve.<sup>7,17,18,20,21</sup> Despite the fact that aggressive debridement may cause complete heart  
49  
50 block requiring permanent pacemaker implantation, debridement of all infected tissue  
51  
52 remains the first priority.  
53  
54  
55  
56

57  
58 One way to minimize the risk of recurrent PVE may be the injection of fibrin glue  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 mixed with antibiotics into the abscess cavity. We employed this technique whenever  
4  
5 we performed patch reconstruction of the aortic annulus, because antibiotics mixed with  
6  
7 fibrin glue are thought to be delivered continuously into the surrounding tissue for the  
8  
9 first few days following surgery.<sup>16</sup> There was no recurrence of PVE in our series,  
10  
11 although this does not conclusively prove the effectiveness of this technique.  
12  
13

14  
15 Other surgical techniques that have been used in the past include valve replacement  
16  
17 with patch closure of the abscess cavity,<sup>17-19</sup> aortic root replacement using a  
18  
19 homograft,<sup>3-7</sup> autograft (the Ross procedure),<sup>8,9</sup> composite-valve conduit,<sup>20,21</sup> Freestyle  
20  
21 stentless bioprosthesis,<sup>13,22</sup> and translocation of the aortic valve with saphenous vein  
22  
23 bypass grafts to the coronary arteries.<sup>23,24</sup>  
24  
25

26  
27 It is well known that both homografts and autografts offer excellent hemodynamic  
28  
29 performance and it is thought that they are resistant to infection. Indeed, the reported  
30  
31 incidence of recurrent PVE after aortic root replacement using homografts or autografts  
32  
33 range from 0% to 4.2% and 0% to 4%, respectively.<sup>3-9</sup> However, persistent infection and  
34  
35 false aneurysms or valve degeneration requiring reoperation can occur even after aortic  
36  
37 root replacement using a homograft.<sup>18,25</sup> Furthermore, the Ross procedure is technically  
38  
39 demanding and increases aortic cross-clamp time and cardiopulmonary bypass time, and  
40  
41 valve dysfunction can occur in both neo aortic valves (in the case of homografts) and  
42  
43 neo pulmonary valve (in the case of homografts or other prostheses).<sup>9</sup> Also, the  
44  
45 longevity of homografts (either for AVR or for PVR in the Ross procedure) remains  
46  
47 unclear, and younger patients may require reoperation at a later date due to structural  
48  
49 valve deterioration. Repeat operation in patients with homografts can be very  
50  
51 challenging because homografts tend to become heavily calcified.<sup>26</sup>  
52  
53  
54  
55  
56

57  
58 In Japan, the most important consideration is the relative scarcity of usable  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 homografts, particularly for emergent or urgent situations. This is the reason we  
4  
5 designed a relatively simple procedure that consists of reconstruction of the aortic  
6  
7 annulus using equine pericardium followed by AVR in patients with PVE complicated  
8  
9 with destruction of the aortic annulus. David et al. reported that there were no recurrent  
10  
11 infections after AVR and patch plasty in patients with PVE and aortic root abscesses,<sup>17</sup>  
12  
13 and Lytle et al. and d'Udekem et al. reported that standard AVR with pericardial patch  
14  
15 reconstruction for PVE was not inferior to aortic root replacement using a  
16  
17 homograft.<sup>18,19</sup> Although we did not compare our procedure with any other surgical  
18  
19 interventions, there were no cardiac-related deaths during hospitalization following our  
20  
21 procedure. Moreover, since there was no recurrence of PVE during the mid-term  
22  
23 follow-up period in our study, the recurrence rate may not be affected by the choice of  
24  
25 the materials used for valve prostheses. Hagl et al. reported that the surgical outcome of  
26  
27 aortic root replacement with a composite graft was superior to that of a homograft for  
28  
29 PVE<sup>20</sup>, and Leyh et al. reported that the outcome of aortic root replacement using a  
30  
31 composite graft was not inferior to that of a homograft.<sup>21</sup> Moreover, several authors  
32  
33 have recently reported good outcomes for AVR in patients with PVE and aortic root  
34  
35 abscess using a Freestyle stentless valve.<sup>9,13,22</sup> Since the handling qualities and  
36  
37 performance of a Freestyle valve are similar to those of a homograft, they recommend  
38  
39 the use of a Freestyle valve.<sup>13,22</sup> A composite graft or Freestyle stentless valve can serve  
40  
41 as a good alternative to a homograft for aortic root replacement. However, because  
42  
43 prosthetic valve infection does not usually extend to the sinus of Valsalva or coronary  
44  
45 ostium in most patients with PVE complicated with aortic root abscess,<sup>2-9,12-15,17-25</sup> we  
46  
47 do not believe that aortic root replacement is always necessary.

48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58 Another technical issue to consider is where to anchor the prosthetic valve on the  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 fragile annulus for stability. We anchored the valve with mattress sutures that were  
4  
5 passed through both the patch and the aortic wall whenever we performed patch plasty  
6  
7 of the aortic annulus. There were no postoperative complications due to valve  
8  
9 dehiscence. Also, in early or mid-term follow-up, there were no re-reoperations,  
10  
11 excluding one case who underwent mitral annuloplasty and redo AVR mainly due to  
12  
13 severe functional mitral regurgitation.  
14  
15  
16  
17  
18

## 19 **Conclusion**

20  
21  
22 Patients with PVE complicated with an aortic root abscess can be treated safely with  
23  
24 patch reconstruction of the aortic annulus and AVR. The early and mid-term outcomes  
25  
26 are satisfactory without any recurrence of endocarditis.  
27  
28  
29  
30

## 31 **References**

- 32  
33  
34 1. Bayer AS, Bolger AF, Taubert KA, Wilson W, Steckelberg J, Karchmer AW, et al.  
35  
36 Diagnosis and management of infective endocarditis and its complications. *Circulation*  
37  
38 1998;98:2936-48.  
39  
40  
41 2. Baumgartner FJ, Omari BO, Robertson JM, Nelson RJ, Pandya A, Pandya A, et al.  
42  
43 Annular abscesses in surgical endocarditis: anatomic, clinical, and operative features.  
44  
45 *Ann Thorac Surg* 2000;70:442-7.  
46  
47  
48 3. Petrou M, Wong K, Albertucci M, Brecker SJ, Yacoub MH. Evaluation of unstented  
49  
50 aortic homografts for the treatment of prosthetic aortic valve endocarditis. *Circulation*  
51  
52 1994;90:II 198-204.  
53  
54  
55 4. McGiffin DC, Kirklin JK. The impact of aortic valve homografts on the treatment of  
56  
57 aortic prosthetic valve endocarditis. *Semin Thorac Cardiovasc Surg* 1995;7:25-31.  
58  
59  
60  
61  
62  
63  
64  
65

- 1  
2  
3 5. Dossche KM, Defauw JJ, Ernst SM, Craenen TW, De Jongh BM, de la Rivière AB.  
4  
5 Allograft aortic root replacement in prosthetic aortic valve endocarditis: a review of 32  
6  
7 patients. *Ann Thorac Surg* 1997;63:1644-9.  
8  
9
- 10 6. Yankah AC, Pasic M, Klose H, Siniawski H, Weng Y, Hetzer R. Homograft  
11  
12 reconstruction of the aortic root for endocarditis with periannular abscess: a 17-year  
13  
14 study. *Eur J Cardiothorac Surg* 2005;28:69-75.  
15  
16
- 17 7. Lopes S, Calvino P, de Oliveira F, Antunes M. Allograft aortic root replacement in  
18  
19 complex prosthetic endocarditis. *Eur J Cardiothorac Surg* 2007;32:126-30.  
20  
21
- 22 8. Pettersson G, Tingleff J, Joyce FS. Treatment of aortic valve endocarditis with the  
23  
24 Ross operation. *Eur J Cardiothorac Surg* 1998;13:678-4.  
25  
26
- 27 9. Okada K, Tanaka H, Takahashi H, Morimoto N, Munakata H, Asano M, et al. Aortic  
28  
29 root replacement for destructive aortic valve endocarditis with left ventricular-aortic  
30  
31 discontinuity. *Ann Thorac Surg* 2008;85:940-5.  
32  
33
- 34 10. Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective  
35  
36 endocarditis: utilization of specific echocardiographic findings. *Duke Endocarditis*  
37  
38 *Service. Am J Med* 1994;96:200-9.  
39  
40
- 41 11. David TE. The surgical treatment of patients with prosthetic valve endocarditis.  
42  
43 *Semin Thorac Cardiovasc Surg* 1995;7:47-53.  
44  
45
- 46 12. Glazier JJ, Verwilghen J, Donaldson RM, Ross DN. Treatment of complicated  
47  
48 prosthetic aortic valve endocarditis with annular abscess formation by homograft aortic  
49  
50 root replacement. *J Am Coll Cardiol* 1991;17:1177-82.  
51  
52
- 53 13. Müller LC, Chevtchik O, Bonatti JO, Müller S, Fille M, Laufer G. Treatment of  
54  
55 destructive aortic valve endocarditis with the Freestyle Aortic Root Bioprosthesis. *Ann*  
56  
57 *Thorac Surg* 2003;75:453-6.  
58  
59  
60  
61  
62  
63  
64  
65

- 1  
2  
3 14. Wang A, Athan E, Pappas PA, Fowler VG Jr, Olaison L, Paré C, et al. Contemporary  
4  
5 clinical profile and outcome of prosthetic valve endocarditis. *JAMA* 2007;297:1354-61.  
6
- 7 15. Romano G, Carozza A, Della Corte A, De Santo LS, Amarelli C, Torella M, et al.  
8  
9 Native versus primary prosthetic valve endocarditis: comparison of clinical features and  
10  
11 long-term outcome in 353 patients. *J Heart Valve Dis* 2004;13:200-8.  
12
- 13 16. Kram HB, Bansal M, Timberlake O, Shoemaker WC. Antibacterial effects of fibrin  
14  
15 glue-antibiotic mixtures. *J Surg Res* 1991;50:175-8.  
16
- 17 17. David TE, Komeda M, Bronfman PR. Surgical treatment of aortic root abscess.  
18  
19 *Circulation* 1989;80:I269-74  
20
- 21 18. d'Udekem Y, David TE, Feindel CM, Armstrong S, Sun Z. Long-term results of  
22  
23 operation for paravalvular abscess. *Ann Thorac Surg* 1996;62:48-53.  
24
- 25 19. Lytle BW, Priest BP, Taylor PC, Loop FD, Sapp SK, Stewart RW, et al. Surgical  
26  
27 treatment of prosthetic valve endocarditis. *J Thorac Cardiovasc Surg* 1996;111:198-207.  
28
- 29 20. Hagl C, Galla JD, Lansman SL, Fink D, Bodian CA, Spielvogel D, et al. Replacing  
30  
31 the ascending aorta and aortic valve for acute prosthetic valve endocarditis: is using  
32  
33 prosthetic material contraindicated? *Ann Thorac Surg* 2002;74:S1781-5.  
34
- 35 21. Leyh RG, Knobloch K, Hagl C, Ruhparwar A, Fischer S, Kofidis T, et al.  
36  
37 Replacement of the aortic root for acute prosthetic valve endocarditis: prosthetic  
38  
39 composite versus aortic allograft root replacement. *J Thorac Cardiovasc Surg*  
40  
41 2004;127:1416-20.  
42
- 43 22. Fukui T, Suehiro S, Shibata T, Hattori K, Hirai H, Aoyama T. Aortic root  
44  
45 replacement with Freestyle stentless valve for complex aortic root infection. *J Thorac*  
46  
47 *Cardiovasc Surg* 2003;125:200-3.  
48
- 49 23. Nottin R, Al-Attar N, Ramadan R, Azmoun A, Therasse A, Kortas C, et al. Aortic  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 valve translocation for severe prosthetic valve endocarditis: early results and long-term  
4  
5 follow-up. *Ann Thorac Surg* 2005;79:1486-90.  
6

7  
8 24. Reitz BA, Stinson EB, Watson DC, Baumgartner WA, Jamieson SW. Translocation  
9  
10 of the aortic valve for prosthetic valve endocarditis. *J Thorac Cardiovasc Surg*  
11  
12 1981;81:212-8.  
13

14  
15 25. Gabbieri D, Dohmen PM, Linneweber J, Grubitzsch H, von Heymann C, Neumann  
16  
17 K, et al. Early outcome after surgery for active native and prosthetic aortic valve  
18  
19 endocarditis. *J Heart Valve Dis* 2008;17:508-24.  
20

21  
22 26. Joudinaud TM, Baron F, Raffoul R, Pagis B, Vergnat M, Parisot C, et al. Redo aortic  
23  
24 root surgery for failure of an aortic homograft is a major technical challenge. *Eur J*  
25  
26 *Cardiothorac Surg* 2008;33:989-994.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



1  
2  
3 **Figure legend**  
4

5 **Figure 1:** Schemas of abscess cavity site (black shading)  
6

7 LCA: left coronary artery ostium; NCC: non coronary cusp; RCA: right coronary artery  
8  
9 ostium  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Table1

Table 1. Patients Demographics and Preoperative Echocardiographic Data (n=8)

No	Gender	Age	NYHA	Previous Operation	Cultures	LVEF (%)	AR Grade	Mitral valve endocarditis	Indication for operation
1	M	68	IV	AVR (Mosaic23), CABG	Unknown	25	III	No	Worsening CHF
2	M	76	III	AVR (CEP23)	MRSE	74	III	No	Uncontrollable infection
3	M	74	III	AVR (CEP23)	MRSE	70	I	No	Uncontrollable infection
4	M	53	III	AVR (CEP27)	MSSE	59	I	No	Uncontrollable infection, peripheral emboli
5	M	63	III	AVR (CEP25), CABG	MRSE	56	IV	No	Uncontrollable infection, severe AR
6	M	60	IV	AVR (SJM23), MVR (CM31), TAP, MAZE	MRSE	65	III	Yes	Uncontrollable infection
7	M	71	IV	AVR(CEP25), MAP, TAP, MAZE	MRSE	35	I	Yes	Uncontrollable infection
8	F	84	IV	AVR (Magna19)	Unknown	68	II	No	Uncontrollable infection

AR: aortic regurgitation; AVR: aortic valve replacement; CABG: coronary artery bypass grafting; CEP: Carpentier-Edwards Pericardial; CHF: congestive heart failure; CM: CarboMedics; LVEF: left ventricular ejection fraction; MAP: mitral annuloplasty; MRSE: methicillin-resistant *Staphylococcus epidermidis*; MSSE: methicillin-sensitive *Staphylococcus epidermidis*; MVR: mitral valve replacement; NYHA: New York Heart Association; TAP; tricuspid annuloplasty

Table 2. Operative and Postoperative Results (n=8)

No	IABP	Aorto-LV discontinuity	Valve	Annulus Reconstruction	Combined Procedure	Complications	Follow up	Recurrent PVE
1	Yes	No	Mosaic 23	Direct	Graft replacement of ascending aorta	AF	8 months	No
2	No	Yes	CEP 21	Patch			32 months	No
3	No	No	CEP 21	Direct			49 months	No
4	No	Yes	CM 25	Patch		Transient AV block	48 months	No
5	No	Yes	CM 21	Patch			45 months	No
6	Yes	Yes	CM 21	Patch	MVR, CABG (LAD)	Reexploration for bleeding, AF, pneumonia	6 months	No
7	Yes	No	CEP23	Patch	Removal of vegetation from MV	Gastrointestinal bleeding, prolonged respiratory support	30 months	No
8	No	No	SJM17	Patch		AF, renal failure, pneumonia, tracheostomy	Died on POD 66	No

AF: atrial fibrillation; AV: artioventricular; CABG: coronary artery bypass grafting; CEP: Carpentier-Edwards Pericardial tissue prosthesis; CM: CardioMedics mechanical prosthesis; LAD: left anterior descending artery; MV: mitral valve; MVR: mitral valve replacement; PVE: prosthetic valve endocarditis; SJM: St Jude Medical mechanical valve

Figure  
[Click here to download high resolution image](#)

